We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Alkemy Capital Investments Plc | LSE:ALK | London | Ordinary Share | GB00BMD6C023 | ORD GBP0.02 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 87.50 | 85.00 | 90.00 | 90.00 | 87.50 | 90.00 | 2,726 | 08:00:43 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Offices-holdng Companies,nec | 0 | -2.65M | -0.3239 | -2.70 | 7.14M |
From Nov 2023 to May 2024
TIDMALK TIDMB
On Wednesday, 15 November 2023 ALK (ALKB:DC / OMX: ALK B / AKBLF) releases its nine-month interim report (Q3) 2023.
ALK will host a meeting for analysts and institutional investors that day at 1.30pm (CET) at which Management will review the financial results, the outlook and answer questions.
The meeting will be audio cast live on our website https://ir.alk.net, where the related presentation will be available shortly before the meeting begins.
To register for the conference call, please use this link https://dpregister.com/sreg/10183783/fad25cbd21 and follow the instructions. You will receive an email from diamondpass@choruscall.com with dial-in details, including a passcode and a pin code. Please make sure to whitelist diamondpass@choruscall.com https://www.globenewswire.com/Tracker?data=GNrZbo7xgxj8sOdfiEN3ojhmq8TVGaHk-M5da0bIawXPKNaG4ZUo8eg3vSKu2_qgFqFiNeM08CE27YiFjFRbVX0YWdnfwIS9JsfPj3A9nfOe4o0Axg3CS9Jb2FpM5igf and/or check your spam filter. We advise you to register on the day before the call at the latest.
ALK-Abelló A/S
For further information please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Maiken Riise Andersen, tel. +45 5054 1434
About ALK
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,700 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.
Attachment
Hot Features
Premium
-- InvestorNews_09Nov23
https://ml-eu.globenewswire.com/Resource/Download/6fd2d8ff-9526-4a17-afa0-5c5da5a78170
(END) Dow Jones Newswires
November 09, 2023 07:46 ET (12:46 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Alkemy Capital Investments Chart |
1 Month Alkemy Capital Investments Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
